FDA’s Expert Vaccine Panel Releases New Determinations on Booster Doses for Pfizer-BioNTech COVID-19 Vaccine
September 20, 2021
The FDA’s vaccine expert panel, the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, met to review an application from Pfizer and BioNTech for a third dose of their messenger RNA vaccine, to be given six months after the completion of the primary series. They have recommended a booster dose for the following individuals:
- 65 years of age and older
- at high risk of severe COVID-19
Those at high risk of severe illness include people who have:
- Been receiving active cancer treatment for tumors or cancers of the blood
- Received an organ transplant and are taking medicine to suppress the immune system
- Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
- Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response
Committee members advised that those considered at high risk should also include healthcare workers, emergency responders and others who are exposed to the COVID-19 virus by their jobs.
Texas MedClinic offers the Pfizer BioNTech vaccine to those 12 years and older at all 19 clinics. Those who are ages 12-17 must be accompanied by a legal guardian. Click here to find your nearest location and Check-In Online.